Abstract:In December 2021, the U.S. Food and Drug Administration (FDA) issued emergency use authorizations (EUAs) for two oral antiviral at-home treatments for coronavirus disease 2019 (COVID-19), nirmatrelvir/ritonavir (Paxlovid [Pfizer]), and molnupiravir (Merck).[1] While their mechanisms of action somewhat differ, these agents are considered "game-changers" by some observers, since they do not require administration by intravenous infusion as monoclonal antibodies do. Initial efficacy studies suggest that nirmatrelvir/ritonavir may be more effective than molnupiravir,[1] but it also has more drug interactions of potential concern, especially related to anticoagulant therapy.[1] Molnupiravir does not have any reported interaction with anticoagulant agents.[2] Additionally, remdesivir (Veklury [Gilead]) and bebtelovimab (Lilly) are parenteral agents recently granted an EUA for use in the outpatient setting as treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, who are at high risk for progression to severe COVID-19, including hospitalization or death.[3] Neither of these agents have any known interaction with anticoagulants.[2] Nirmatrelvir/ritonavir is comprised of nirmatrelvir, a SARS-CoV-2 main protease inhibitor, co-packaged with ritonavir, a protease inhibitor.[4] While ritonavir has no activity against SARS-CoV-2, its inhibition of CYP3A-mediated metabolism of nirmatrelvir increases nirmatrelvir plasma concentrations to levels anticipated to inhibit SARS-CoV-2 replication. Outpatient nirmatrelvir/ritonavir use is authorized for treatment of mild to moderate COVID-19 disease in adults and pediatric patients older than 12 and weighting more than 40 kg who are at high risk for severe progression of COVID-19. Regarding pharmacokinetics, nirmatrelvir is primarily eliminated by the kidneys, with minimal liver metabolism.[4] However, ritonavir is known to be an inhibitor of cytochrome P450 (CYP) isoenzymes, particularly a strong CYP3A4 and weak 2D6 inhibitor, and an inhibitor of P-glycoprotein (P-gp).[5] [6] Additionally, ritonavir is an inducer of CYP 1A2, 2B6, 2C19, and 2C9.[5] On that premise, the risk of drug interactions with nirmatrelvir/ritonavir and many commonly used medications, including statins and antiarrhythmic drugs, may preclude its use or need careful adjustment of dosing. Additionally, the FDA label flags two anticoagulants for nirmatrelvir/ritonavir users, rivaroxaban and warfarin, while other direct oral anticoagulants (DOACs) are not mentioned. Inhibition of CYP3A4 and P-gp leads to increased plasma levels and pharmacodynamic effects of rivaroxaban, thus potentially increasing bleeding risk (area under the curve [AUC] change 153%, maximum concentration ( C max ) change 53%).[7] Antiplatelet or anticoagulant therapy is not currently recommended for outpatients with COVID-19, the largest population of individuals infected.[3] [8] [9] The ACTIV-4B Outpatient Thrombosis Prevention Trial,[10] aimed at evaluating antithrombotic therapy in outpatients with COVID-19, was a randomized, adaptive, double-blind, placebo-controlled trial that randomly assigned outpatients with COVID-19 in a 1:1:1:1 ratio to receive aspirin (81 mg orally once daily), prophylactic-dose apixaban (2.5 mg orally twice daily), therapeutic-dose apixaban (5 mg orally twice daily), or matching placebo for 45 days. Treatment with aspirin or apixaban compared with placebo did not reduce the rate of composite clinical outcomes, with risk of adjudicated primary composite outcome with placebo being 0.0% (95% CI, 0.0–2.8%), with aspirin 0.0% (95% CI, 0.0–2.6%), 0.7% in the prophylactic apixaban group (95% CI, 0.1–4.1%) and 1.4% in therapeutic apixaban group (95% CI, 0.4% −5.0%), respectively. In addition, a phase 2b placebo controlled randomized study of rivaroxaban 10 mg daily in patients with COVID-19 not currently hospitalized or under immediate consideration for hospitalization was terminated, after almost 500 of the target 600 participants were enrolled because a prespecified interim analysis of the first 200 participants in the intent-to-treat population demonstrated it would be futile to attempt to show a beneficial effect of rivaroxaban in this patient population. Disease progression rate with rivaroxaban was 20.7 versus 19.8% in placebo groups, with non-significant risk difference of –1.0 (95% confidence interval, −6.4 to 8.4%; p = 0.78).[11] Thus, at this time, routine anticoagulation is not recommended for patients with COVID-19 who do not need hospitalization. Despite these findings, patients at high risk of thrombosis are usually prescribed long-term anticoagulation therapy. Moreover, COVID-19 patients who require anticoagulants for atrial fibrillation or flutter, recent surgery or immobility, heart valve replacement, ischemic stro -Abstract Truncated-

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19

Nirmatrelvir/ritonavir for Patients with SARS-CoV-2 Infection and Impaired Kidney Function During the Omicron Surge

High concentrations of nirmatrelvir/ritonavir in critically ill patients receiving continuous renal replacement therapy

Efficacy and Safety of Nirmatrelvir/Ritonavir in Severe Hospitalized Patients with COVID-19 and in Patients at High Risk for Progression to Critical Illness: A Real-World Study

A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing

Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19

Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study

Proposal for a Simple Algorithmic Approach to Manage Drug–Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients

Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients

The effectiveness of nirmatrelvir/ritonavir regimen in hospitalized renal transplant patients with prolonged COVID-19 infection: a multicenter clinical experience

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?

Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System

A Simple and Rapid LC-MS/MS Method for the Quantification of Nirmatrelvir/Ritonavir in Plasma of Patients with COVID-19

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system

Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19

Population Pharmacokinetics of Nirmatrelvir in Chinese Patients with COVID-19: Therapeutic Drug Monitoring and Dosing Regimen Selection in Clinical Practice

Real-World Effectiveness of Nirmatrelvir/Ritonavir and Dexamethasone among Hospitalized Patients with COVID-19: A Prospective Cohort Study.

Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study